Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient.

[1]  J. Moon,et al.  Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[2]  R. Desnick,et al.  Evolution of cardiac pathology in classic Fabry disease: Progressive cardiomyocyte enlargement leads to increased cell death and fibrosis, and correlates with severity of ventricular hypertrophy‬‬‬‬‬‬‬‬. , 2017, International journal of cardiology.

[3]  L. Cowart,et al.  Lipotoxic very‐long‐chain ceramides cause mitochondrial dysfunction, oxidative stress, and cell death in cardiomyocytes , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  S. Chiou,et al.  Energy utilization of induced pluripotent stem cell-derived cardiomyocyte in Fabry disease. , 2017, International journal of cardiology.

[5]  T. Murohara,et al.  Long-Term Pathological Follow-Up of Myocardium in a Carrier of Duchenne Muscular Dystrophy With Dilated Cardiomyopathy. , 2017, Circulation. Heart failure.

[6]  Hsin-Yang Li,et al.  Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation , 2016, Oncotarget.

[7]  D. Lockhart,et al.  Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. , 2016, The New England journal of medicine.

[8]  A. Hagège,et al.  X‐chromosome inactivation in female patients with Fabry disease , 2016, Clinical genetics.

[9]  H. Sakuraba,et al.  Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease , 2015, PloS one.

[10]  M. Russo,et al.  Increased oxidative stress contributes to cardiomyocyte dysfunction and death in patients with Fabry disease cardiomyopathy. , 2015, Human pathology.

[11]  M. Beck,et al.  Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment , 2015, Orphanet Journal of Rare Diseases.

[12]  C. Vargas,et al.  DNA damage in Fabry patients: An investigation of oxidative damage and repair. , 2015, Mutation research. Genetic toxicology and environmental mutagenesis.

[13]  S. Packman,et al.  Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease , 2015, Journal of Medical Genetics.

[14]  A. Mehta,et al.  Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis , 2015, Molecular genetics and metabolism reports.

[15]  J. Deleuze,et al.  Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease , 2014, Journal of Inherited Metabolic Disease.

[16]  A. Futerman,et al.  Ceramide synthases as potential targets for therapeutic intervention in human diseases. , 2014, Biochimica et biophysica acta.

[17]  M. Dijkgraaf,et al.  Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis , 2014, Journal of Inherited Metabolic Disease.

[18]  Y. Eto,et al.  Morphological features of iPS cells generated from Fabry disease skin fibroblasts using Sendai virus vector (SeVdp). , 2013, Molecular genetics and metabolism.

[19]  S. Yamanaka,et al.  Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[20]  M. Suematsu,et al.  Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. , 2013, Cell stem cell.

[21]  Julie V. Harness,et al.  Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. , 2012, Cell stem cell.

[22]  K. Eggan,et al.  Erosion of dosage compensation impacts human iPSC disease modeling. , 2012, Cell stem cell.

[23]  C. A. Fossati,et al.  Higher apoptotic state in Fabry disease peripheral blood mononuclear cells.: effect of globotriaosylceramide. , 2011, Molecular genetics and metabolism.

[24]  C. Murry,et al.  Heart regeneration , 2011, Nature.

[25]  Noel Southall,et al.  High Throughput Screening for Inhibitors of Alpha-Galactosidase , 2010, Current chemical genomics.

[26]  D. Germain.  Fabry disease , 2010, Orphanet journal of rare diseases.

[27]  K. Plath,et al.  Female human iPSCs retain an inactive X chromosome. , 2010, Cell stem cell.

[28]  Shinsuke Yuasa,et al.  Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. , 2010, Cell stem cell.

[29]  F. Cecchi,et al.  Cardiovascular events in patients with fabry disease natural history data from the fabry registry. , 2010, Journal of the American College of Cardiology.

[30]  Manesh R. Patel,et al.  Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry , 2009, Genetics in Medicine.

[31]  I. Komuro,et al.  Developmental stage-specific biphasic roles of Wnt/β-catenin signaling in cardiomyogenesis and hematopoiesis , 2006, Proceedings of the National Academy of Sciences.

[32]  A. Moorman,et al.  Expression and regulation of the atrial natriuretic factor encoding gene Nppa during development and disease. , 2005, Cardiovascular research.

[33]  H. Tojo.  Properties of an electrospray emitter coated with material of low surface energy. , 2004, Journal of chromatography. A.

[34]  H. Tojo,et al.  Alteration of the 4-sphingenine scaffolds of ceramides in keratinocyte-specific Arnt-deficient mice affects skin barrier function. , 2003, The Journal of clinical investigation.

[35]  J. Ross,et al.  Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Satoshi Ishii,et al.  Galactose stabilizes various missense mutants of α-galactosidase in Fabry disease , 1995 .

[37]  J. Scheerer,et al.  Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease. , 1981, Clinica chimica acta; international journal of clinical chemistry.

[38]  I. Komuro,et al.  Generation of Induced Pluripotent Stem Cells From Patients With Duchenne Muscular Dystrophy and Their Induction to Cardiomyocytes. , 2016, International heart journal.

[39]  S. Yamanaka,et al.  An Efficient Nonviral Method to Generate Integration‐Free Human‐Induced Pluripotent Stem Cells from Cord Blood and Peripheral Blood Cells , 2013, Stem cells.

[40]  H. Tojo,et al.  Identification and analysis of novel glycolipids in vertebrate brains by HPLC/mass spectrometry. , 2006, Methods in enzymology.

[41]  R. Desnick.  α-Galactosidase A deficiency. Fabry disease , 2001 .

[42]  W. Christie.  Separation of lipid classes by high-performance liquid chromatography with the "mass detector". , 1986, Journal of chromatography.